Compare Citius Pharmaceuticals Inc (CTXR) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Warner Music Group Corp trades at $28.89 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 1110.1× Citius Pharmaceuticals Inc's market cap, and Warner Music Group Corp pays a 2.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Warner Music Group Corp for 96 Days on average.
| CTXR | WMG | |
|---|---|---|
Market Cap | $13.62M | $15.12B |
Volume | 132,438 | 2,966,414 |
Sector | Health | Media |
52-Week High | $1.82 | $34.72 |
52-Week Low | $0.48 | $23.65 |
Typical Hold Time | 16 Days | 96 Days |
Enterprise Value | $3.79M | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Warner Music Group (WMG) trades at $28.16, up 1.99% today, with a bullish technical signal and strong analyst support. Recent earnings show revenue growth to $6.71B in 2025, though net income margin dipped to 5.44%. The company is actively engaging in AI partnerships and licensing renewals, positioning for future growth in the evolving media landscape.
The outlook for WMG is positive, driven by streaming growth and strategic AI initiatives, with a consensus price target of $39.50 implying significant upside. Risks include margin pressure and competitive dynamics in the music industry, but institutional buying and a 'Moderate Buy' consensus suggest confidence in its long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
